fatty acid oxidation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-15. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
| Property | Value | Notes |
|---|---|---|
| WADA classification | S4 Hormone and Metabolic Modulators | Prohibited at all times in sport. |
| Drug approval status | Not approved in major jurisdictions | No accepted therapeutic indication. |
| Common detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Typical test matrix | Urine or blood | Urine is common in anti-doping testing. |
| Product labeling | Research chemical or supplement | Often not independently verified. |
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Narrated by actress Miranda Richardson 27 November Dismantling the Bomb, Pantex in Texas; START II in January 1993; Ted Taylor (physicist); eighteen scientists from the UK worked on the Manhattan Project; the plutonium fissile material, which was half the world's supply, for the July Trinity (nuclear test) was carried on the back seat of a car, to be assembled; the bomb was hoisted on 14 July 1945; a warning flare was fired, then the electrical circuits were connected at 5.29am on 16 July 1945; the bomb was dropped twenty one days later, exploding at 1,900 feet; the Russians developed the bomb through the work of Igor Kurchatov and Yulii Khariton; much American nuclear weapon research also took place at Livermore, California; the first British nuclear test, on 3 October 1952, was set up by two people on HMS Plym; many US weapon cores had been made at the Rocky Flats Plant in Colorado; Viktor Mikhailov (politician), Russian minister of nuclear power; the Nuclear Control Institute. Narrated by Scottish actor Tom Cotcher, produced by Chris Haws, directed by Richard Melman, made by InCA Productions 4 December Electric Skies, about lightning at the Langmuir Laboratory for Atmospheric Research; electrical engineer Martin A.
"Attogram sensing of trinitrotoluene with a self-assembled molecular gelator". Journal of the American Chemical Society. 134 (10): 4834–4841. doi:10.1021/ja210728c. PMID 22352376. SS Babu, VK Praveen, Ajayaghosh, Ayyappanpillai (2014). “Functional π-gelators and their applications”. Chem. Rev. 2014, 114, 4, 1973-2129. https://doi.org/10.1021/cr400195e R, D, Mukhopadhyay.; and Ajayaghosh, Ayyappanpillai (2015). “Living supramolecular polymerization”. Science 2015, 349, 241.doi:10.1126/science.aac7422 S, Prasanthkumar.; S, Ghosh.; V, C, Nair.; A, Saeki.; S, Seki.; and Ajayaghosh Ayyappanpillai (2015). “Organic Donor-Acceptor Assemblies to Coaxial p-n Heterojunctions with High Photoconductivity”. Angew. Chem., Int. Ed. 2015, 54, 946-950. https://doi.org/10.1002/anie.201408831. B, Vedhanarayanan.; V, S, Nair.; V, C, Nair.; and Ajayaghosh, Ayyappanpillai (2016). “Formation of Coaxial Nanocables with Amplified Supramolecular Chirality through an Interaction between Carbon Nanotubes and a Chiral p-Gelator”. Angew. Chem., Int. Ed. 2016, 55, 10345-10349. https://doi.org/10.1002/anie.201605354. V, S, Nair.; R, D, Mukhopadhyay.; A, Saeki.; S, Seki.; and Ajayaghosh, Ayyappanpillai (2016). “A p-Gel Scaffold for Assembling Fullerene to Photoconducting Supramolecular Rods: Non-Equilibrium Self-Assembly of C60 in a p-Gel”. Science Advances 2016, 2, e1600142. doi:10.1126/sciadv.1600142 R, D, Mukhopadhyay.; B, Vedhanarayanan.; and Ajayaghosh, Ayyappanpillai (2017). “Creation of 'Rose Petal' and 'Lotus Leaf' Effects on Alumina by Surface Functionalization and Metal Ion Coordination”. Angew.
=== Pharmacodynamics === Research has shown that salvinorin A is a potent κ-opioid receptor (KOR) agonist (Ki = 2.4 nM, EC50 = 1.8 nM). It has a high affinity for the receptor, indicated by the low dissociation constant of 1.0 nanomolar (nM). It shows atypical properties as an agonist of the KOR relative to other KOR agonists. In addition to its KOR agonism, salvinorin A has been found to act as a dopamine D2 receptor partial agonist, with an affinity of 5–10 nM, an intrinsic activity of 40–60%, and an EC50 of 48 nM. As such, the dopamine D2 receptor might also play a role in its effects. Salvinorin A has no action at the 5-HT2A serotonin receptor, the principal molecular target responsible for the actions of 'classical' psychedelics such as LSD and mescaline. Salvinorin A has also been shown to have effect on cannabinoid CB1 receptors. It significantly increases prolactin and inconsistently increases cortisol. It causes dysphoria by stopping release of dopamine in the striatum. Salvinorin A increases activity of DAT while decreasing activity of SERT. Salvinorin A is capable of inhibiting excess intestinal motility (e.g. diarrhea), through its potent κ-opioid-activating effects. The mechanism of action for salvinorin A on ileal tissue has been described as 'prejunctional', as it was able to modify electrically induced contractions, but not those of exogenous acetylcholine.
Sources: en.wikipedia.org
== Structure == The sinoatrial node is a crescent-shaped structure located in the subepicardial layer of the right atrium. The size of the SA node varies by individual but is approximately 10-20 mm long and 2–3 mm in width, positioned laterally to the entrance of the superior vena cava. The widest part of the structure is at its superior 'head' and then tapers as it follows the sulcus terminalis toward the inferior vena cava. Structurally the SA node consists of a network of pacemaker cells that are embedded within a dense matrices of connective tissue that increases in density as age increases.
Foremost is the incorporation of radionuclides into the metal-organic framework as the metal nodes. This effectively captures the actinides by incorporating them into the rigid crystal structure itself, locking it in place. The incoperation of actinides as metal nodes can be achieved through a variety of methods, including synthesis, metal-node extension, and cation exchange. Actinide-containing metal-organic frameworks can be synthesized directly from actinide salts, allowing for direct incorporation without further or previous modification required. Additionally, the metal-node can be extended, allowing for a combination of actinides and transition metals to serve as the nodes simultaneously. Finally, actinides can be incorporated into the metal node through cation exchange; a previously-synthesized metal-organic framework is exposed to actinide cations, where the radionuclides are allowed to slowly replace the transition metal as the metal nodes, incorporating themselves into the crystal itself. Another known method by which metal-organic frameworks capture radionuclides is through the binding/anchoring of these cations to functionalized organic linkers. These organic linkers commonly utilize nucleophilic moieties known to bind and anchor to cations; such moieties include carboxylic acid groups and crown ethers. This binding/anchoring drastically slows the rate of actinides leaching from the framework. For example, carboxylic acid-functionalized linkers have been used to drastically slow the leaching of 241Am into dimethylformamide from a zirconium-based framework.
Common aqueous acids include hydrochloric acid (a solution of hydrogen chloride that is found in gastric acid in the stomach and activates digestive enzymes), acetic acid (vinegar is a dilute aqueous solution of this liquid), sulfuric acid (used in car batteries), and citric acid (found in citrus fruits). As these examples show, acids (in the colloquial sense) can be solutions or pure substances, and can be derived from acids (in the strict sense) that are solids, liquids, or gases. Strong acids and some concentrated weak acids are corrosive, but there are exceptions such as carboranes and boric acid. The second category of acids are Lewis acids, which form a covalent bond with an electron pair. An example is boron trifluoride (BF3), whose boron atom has a vacant orbital that can form a covalent bond by sharing a lone pair of electrons on an atom in a base, for example the nitrogen atom in ammonia (NH3). Lewis considered this as a generalization of the Brønsted definition, so that an acid is a chemical species that accepts electron pairs either directly or by releasing protons (H+) into the solution, which then accept electron pairs. Hydrogen chloride, acetic acid, and most other Brønsted–Lowry acids cannot form a covalent bond with an electron pair, however, and are therefore not Lewis acids. Conversely, many Lewis acids are not Arrhenius or Brønsted–Lowry acids. In modern terminology, an acid is implicitly a Brønsted acid and not a Lewis acid, since chemists almost always refer to a Lewis acid explicitly as such.
=== Trapped ion mobility spectrometry === In trapped ion mobility spectrometry (TIMS), ions are held stationary (or trapped) in a flowing buffer gas by an axial electric field gradient (EFG) profile while the application of radio frequency (rf) potentials results in trapping in the radial dimension. TIMS operates in the pressure range of 2 to 5 hPa and replaces the ion funnel found in the source region of modern mass spectrometers. It can be coupled with nearly any mass analyzer through either the standard mode of operation for beam-type instruments or selective accumulation mode (SA-TIMS) when used with trapping mass spectrometry (MS) instruments. Effectively, the drift cell is prolonged by the ion motion created through the gas flow. Thus, TIMS devices do neither require large size nor high voltage in order to achieve high resolution, for instance achieving over 250 resolving power from a 4.7 cm device through the use of extended separation times. However, the resolving power strongly depends on the ion mobility and decreases for more mobile ions. In addition, TIMS can be capable of higher sensitivity than other ion mobility systems because no grids or shutters exist in the ion path, improving ion transmission both during ion mobility experiments and while operating in a transparent MS only mode.
Sources: en.wikipedia.org
Depressants are psychoactive drugs that temporarily diminish the function or activity of a specific part of the body or mind. Colloquially, depressants are known as "downers", and users generally take them to feel more relaxed and less tense. Examples of these kinds of effects may include anxiolysis, sedation, and hypotension. Depressants are widely used throughout the world as prescription medicines and as illicit substances. When these are used, effects may include anxiolysis (reduction of anxiety), analgesia (pain relief), sedation, somnolence, cognitive/memory impairment, dissociation, muscle relaxation, lowered blood pressure/heart rate, respiratory depression, anesthesia, and anticonvulsant effects. Depressants exert their effects through a number of different pharmacological mechanisms, the most prominent of which include potentiation of GABA or opioid activity, and inhibition of adrenergic, histamine or acetylcholine activity. Some are also capable of inducing feelings of euphoria. The most widely used depressant by far is alcohol (i.e. ethanol). Stimulants or "uppers", such as amphetamines or cocaine, which increase mental or physical function, have an opposite effect to depressants. Depressants, in particular alcohol, can precipitate psychosis. A 2019 systematic review and meta-analysis by Murrie et al. found that the rate of transition from opioid, alcohol and sedative induced psychosis to schizophrenia was 12%, 10% and 9% respectively.
== M == MIKES – Mass-analyzed ion kinetic energy spectrometry MS – Mass spectrometer MS – Mass spectrometry MS2 – Mass spectrometry/mass spectrometry, i.e. tandem mass spectrometry MS/MS – Mass spectrometry/mass spectrometry, i.e. tandem mass spectrometry MALDESI – Matrix-assisted laser desorption electrospray ionization MALDI – Matrix-assisted laser desorption/ionization MAII – Matrix-assisted inlet ionization MAIV – Matrix-assisted ionization vacuum MIMS – Membrane introduction mass spectrometry, membrane inlet mass spectrometry, membrane interface mass spectrometry MCP – Microchannel plate MSn – Multiple-stage mass spectrometry MCP – Microchannel plate MPI – Multiphoton ionization MRM – Multiple reaction monitoring
== Medical Uses == Sorafenib is used as an oral drug which inhibits angiogenesis and tumor cell growth in VEGFR-2 and VEGFR-3 (inhibits the phosphorylation), PDGFRβ (platelet-derived growth factor receptor), RAF kinase, FLT3 (Fms-like tyrosine kinase-3) and KIT (stem cell factor receptor). Sorafenib is used in the treatment of advanced renal cell carcinoma. As of October 2018, it is in phase III of clinical trials for hepatocellular carcinoma, metastatic melanoma and non-small cell lung cancer (NSCLC). Sunitinib is an oral drug that inhibits the phosphorylation of all the VEGF receptors, PDGFR-ß, KIT FLT3, CSF1R and GDNF. Sunitinib is used in the treatment of advanced renal cell carcinoma and gastrointestinal stromal tumors. Bevacizumab is a humanized monoclonal antibody, which binds selectively to VEGF. It is used as an injection therapy, often in combination with other drugs. It is used in combination with 5-fluorouracil as a first-line treatment of metastatic carcinoma in the colon or rectum. In advanced non-small cell lung cancer bevacizumab (Avastin) is used as a first-line treatment in combination with paclitaxel and carboplatin. It can also be used in the treatment for breast cancer and kidney cancer. Lenvatinib and vandetanib are used for the treatment of progressive and locally advanced differentiated thyroid cancer (DTC). Pazopanib and axitinib are used orally for the treatment of advanced renal cell carcinoma. Cabozantinib has the same indication but it is only used on patients who have already received an anti-angiogenic therapy.
Sources: en.wikipedia.org
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.
Legality varies by country and context. It lacks marketing approval as a medicine in major countries. Sports organizations prohibit its use at all times.
A certificate of analysis may report identity, purity, and testing methods for a specific batch. It does not guarantee safety or legal status. Independent verification can confirm whether the material matches the label.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.